“Sustained Improvement in Patient-Reported Outcomes with Continued Apremilast Treatment over 104 Weeks in Patients with Moderate to Severe Psoriasis”, J of Skin, vol. 2, no. S1, p. S23, Feb. 2018, doi: 10.25251/skin.2.supp.23.